Cytek Biosciences (CTKB) Gross Profit (2020 - 2026)

Cytek Biosciences' Gross Profit history runs 7 years deep, the most recent figure standing at $21.3 million for Q1 2026.

• Quarterly Gross Profit rose 5.44% year-over-year to $21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.6 million (down 2.49% YoY) and the FY2025 annual result came in at $104.5 million, down 5.98% from the prior year.
• Gross Profit was $21.3 million for Q1 2026 at Cytek Biosciences, down from $32.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $33.7 million in Q4 2024 and bottomed at $20.2 million in Q1 2025.
• A 5-year average of $26.3 million and a median of $26.9 million in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit soared 39.29% — and 2025, when it decreased 12.41%.
• Cytek Biosciences' Gross Profit stood at $29.4 million in 2022, then increased by 12.51% to $33.0 million in 2023, then climbed by 1.83% to $33.7 million in 2024, then slipped by 2.28% to $32.9 million in 2025, then plunged by 35.37% to $21.3 million in 2026.
• Business Quant data shows CTKB's Gross Profit at $21.3 million in Q1 2026, $32.9 million in Q4 2025, and $27.6 million in Q3 2025.